Lyon

• Phase 3 study of belzutifan plus pembrolizumab as adjuvant treatment in renal cell carcinoma (RCC) Ended recruitment
  2023-505023-31-00 5 2023-11-17 Renal cell carcinoma
• Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid-refractory acute graft versus host disease Ended recruitment
  2023-503952-28-00 4 2023-11-13 Steroid refractory Acute Graft versus host Disease
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH … Ended recruitment
  2023-507672-52-00 7 2023-11-07 PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC) and
• A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or Without Platinum Chemotherapy, in Subjects with N … Ended recruitment
  2022-500802-16-00 5 2023-11-01 Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung
• A Phase 1/2 Study of BMS-986449 with and without Nivolumab in Participants with Solid Tumors Ended recruitment
  2023-503484-42-00 7 2023-10-19 Advanced, metastatic, solid malignancy
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• Effect of study drug combined with chemotherapy in patients with locally advanced or metastatic lung cancer with mutated receptor responsibl … Ended recruitment
  2023-504434-22-00 5 2023-10-03 Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous
• Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended recruitment
  2022-502369-10-00 5 2023-10-02 Triple negative metastatic breast cancer
• ELVN-002 in Solid Tumors with a HER2 Genetic Alteration Ended recruitment
  2022-502695-23-00 1 2023-09-27 Phase 1a Monotherapy Dose Escalation and Exploration: HER2 mutant, HE
• Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended recruitment
  2022-502593-17-00 5 2023-09-19 Locally advanced or metastatic hormone receptor (HR)-positive, human e
• A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients with Hormone Recepto … Ended recruitment
  2022-502322-41-00 5 2023-09-12 Metastatic breast cancer
• A study of LOXO-783 in Patients with PIK3CA H1047R-Mutant Advanced Breast Cancer and Other Solid Tumors. Ended recruitment
  2023-509568-81-00 1 2023-07-27 Advanced Breast Cancer and Other Solid Tumors
• A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended recruitment
  2022-501024-20-00 5 2023-07-25 ER+/HER2- Early Breast Cancer
• AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended recruitment
  2024-515479-36-00 5 2023-07-05 Chronic Myeloid Leukemia
• A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY FOR PATIENTS WITH NON-SMALL CEL … Ended recruitment
  2022-502977-41-00 5 2023-06-23 Non-Small Cell Lung Cancer
• A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin … Ended recruitment
  2023-507522-16-00 5 2023-05-22 Metastatic Esophageal or Gastric Cancer
• An early access study of ivosidenib in patients with a pretreated locally advanced or metastatic cholangiocarcinoma Ended recruitment
  2022-501463-40-01 5 2023-05-03 Locally Advanced or Metastatic Cholangiocarcinoma
• IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre … Ended recruitment
  2022-502103-30-00 4 2023-04-25 advanced non-squamous non-small cell lung cancer
• LOGGIC/FIREFLY-2: DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy Ended recruitment
  2024-510742-13-00 5 2023-04-19 Pediatric low-grade glioma harboring an activating RAF alteration requ
• ETOP 18-21 AMAZE-lung: A clinical study exploring the effect of amivantamab and lazertinib plus bevacizumab treatment, in people diagnosed w … Ended recruitment
  2024-512288-29-00 4 2023-04-11 Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous
• A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Patients with Previously Untreated Locally Advanced Unresectable or Met … Ended recruitment
  2023-505816-39-00 4 2023-04-04 Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carci
• (Peak) A Clinical Study of CGT9486+Sunitinib vs Sunitinib in Patients with Gastrointestinal Stromal Tumors Ended recruitment
  2022-500637-80-00 5 2023-03-28 gastrointestinal stromal tumor
• Durvalumab (immunotherapy) maintenance after thoracic chemoradiotherapy (CRT) in frail small cell lung cancer patients whose disease is limi … Ended recruitment
  2024-512224-11-00 4 2023-03-24 Histologically confirmed frail Limited Disease Small Cell Lung Cancer
• CAPTIRALL _ Combination of an Anti-PD1 antibody with CART cells Reinfusion in children, adolescents and young adults with Acute Lymphoblasti … Ended recruitment
  2024-514345-11-00 9 2023-03-15 children, adolescents and young adults with Acute Lymphoblastic Leukem

Showing 529–552 of 875 trials